This year's Wonderland Conference in Miami provided inspiring and sometimes hilarious insights into the integration process of psychedelics entering mainstream...
The company is targeting a listing on the Australian Securities Exchange. The post Exopharm to Buy Tryp Therapeutics in All-Stock Deal appeared first on...
The soon-to-issue patent contains composition of matter and methods of use claims for a family of novel prodrug derivatives of psilocybin. The post Enveric...
A new study looks at emotionally painful, shame-related processes with psychedelic use. The post New Study Looks at Shame, Guilt and the Psychedelic Experience...
Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses. The...
Terran’s new patents cover new psilocybin forms, orally active DMT, and 5-MeO-DMT, and novel forms of ibogaine derivative tabernanthalog. The post Terran...
New patent provides IP protection until at least 2041. Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications. The...
A bipartisan group of congressional lawmakers from both the House and the Senate have added funding for studies of psychedelic therapies into a major defense...
Psychedelics are an opportunity to do better than our past drug control strategies. Adults should be trusted to make the right decisions, but policymakers...
Can psychedelics assist in recovery from eating disorders? The findings are promising, but patients and doctors need to proceed with caution until there...